Tectonic Therapeutic, Inc. TECX · Stock Open Tectonic Therapeutic, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Tectonic Therapeutic, Inc. Analysis (TECX)
Is Tectonic Therapeutic, Inc. a good investment? Tectonic Therapeutic, Inc. (TECX) is currently trading at 20.07 USD. Market analysts have a consensus price target of 71.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Tectonic Therapeutic, Inc. is expected to release its next earnings report on Nov. 5, 2026. The market consensus estimate for Forward EPS is -4.76.
Investor FAQ
Does Tectonic Therapeutic, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Tectonic Therapeutic, Inc.?
Tectonic Therapeutic, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 5, 2026. The company currently has a trailing EPS of -4.57.
Company Profile
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Community Discussion